

Johannes Witjes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7209353/publications.pdf>

Version: 2024-02-01

180
papers

15,874
citations

26626

56
h-index

17588

121
g-index

186
all docs

186
docs citations

186
times ranked

11504
citing authors

#	ARTICLE	IF	CITATIONS
1	Robot-assisted Versus Open Radical Cystectomy in Bladder Cancer: An Economic Evaluation Alongside a Multicentre Comparative Effectiveness Study. <i>European Urology Focus</i> , 2022, 8, 739-747.	3.1	6
2	Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 460-469.	6.4	36
3	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	3.9	19
4	[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1101-1112.	6.4	25
5	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103.	1.9	158
6	Predicting surgical outcome in posterior retroperitoneoscopic adrenalectomy with the aid of a preoperative nomogram. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 6507-6515.	2.4	2
7	Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent. <i>BJU International</i> , 2022, 130, 764-775.	2.5	3
8	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022, 8, 113-117.	0.4	2
9	Limited Changes in Lifestyle Behaviours after Non-Muscle Invasive Bladder Cancer Diagnosis. <i>Cancers</i> , 2022, 14, 960.	3.7	6
10	Use of perioperative treatment (tx) among patients (pts) undergoing radical resection (RR) for muscle-invasive urothelial cancer (MIUC) in France, Germany, Italy, Spain, the United Kingdom, the United States, Canada, China, and Japan.. <i>Journal of Clinical Oncology</i> , 2022, 40, 467-467.	1.6	0
11	Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. <i>European Urology Focus</i> , 2022, 8, 1643-1649.	3.1	9
12	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	3.1	7
13	Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study. <i>European Urology</i> , 2022, , .	1.9	0
14	Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100553.	1.7	11
15	Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. <i>ESMO Open</i> , 2022, 7, 100416.	4.5	10
16	The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. <i>Bladder Cancer</i> , 2022, , 1-17.	0.4	2
17	Learning Curve Analysis for Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section Scientific Working Group. <i>European Urology Open Science</i> , 2022, 39, 55-61.	0.4	17
18	International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 82, 34-46.	1.9	30

#	ARTICLE	IF	CITATIONS
19	The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 344.e1-344.e9.	1.6	5
20	Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. <i>European Urology</i> , 2022, 5, 505-516.	5.4	18
21	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	1.9	1,152
22	Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. <i>BJU International</i> , 2021, 127, 198-204.	2.5	21
23	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 423-430.	3.9	37
24	Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality Benefit. <i>European Urology</i> , 2021, 79, 316.	1.9	0
25	Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. <i>European Urology Oncology</i> , 2021, 4, 93-101.	5.4	25
26	Multiparametric Magnetic Resonance Imaging Should Be Preferred Over Digital Rectal Examination for Prostate Cancer Local Staging and Disease Risk Classification. <i>Urology</i> , 2021, 147, 205-212.	1.0	23
27	Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 319-327.	1.6	15
28	Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 377.	3.7	13
29	DPPG2-Based Thermosensitive Liposomes with Encapsulated Doxorubicin Combined with Hyperthermia Lead to Higher Doxorubicin Concentrations in the Bladder Compared to Conventional Application in Pigs: A Rationale for the Treatment of Muscle-Invasive Bladder Cancer. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 75-88.	6.7	17
30	DPPG2-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo. <i>International Journal of Hyperthermia</i> , 2021, 38, 1415-1424.	2.5	3
31	Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. <i>BJU International</i> , 2021, 128, 511-518.	2.5	4
32	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	7.0	53
33	Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study. <i>European Urology</i> , 2021, 79, 609-618.	1.9	32
34	A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection. <i>Bladder Cancer</i> , 2021, 7, 221-241.	0.4	3
35	External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging. <i>BJU International</i> , 2021, 128, 236-243.	2.5	10
36	Low Risk of Severe Complications After a Single, Post-Operative Instillation of Intravesical Chemotherapy in Patients with TaG1G2 Urothelial Bladder Carcinoma. <i>Bladder Cancer</i> , 2021, 7, 193-203.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Patient-reported outcomes and health-related quality of life after urinary diversions. Current Opinion in Urology, 2021, Publish Ahead of Print, 574-579.	1.8	2
38	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine, 2021, 384, 2102-2114.	27.0	427
39	100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. Nature Reviews Urology, 2021, 18, 611-622.	3.8	80
40	Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. European Urology, 2021, 80, 113.	1.9	0
41	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncology, 2021, 17, 3137-3150.	2.4	21
42	Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. Cancers, 2021, 13, 4378.	3.7	35
43	Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer. Journal of Patient-Reported Outcomes, 2021, 5, 96.	1.9	5
44	Device-Assisted Therapies for Nonmuscle-Invasive Bladder Cancer: A Practical Approach. , 2021, , 103-110.		0
45	Follow-up in non-muscle invasive bladder cancer: facts and future. World Journal of Urology, 2021, 39, 4047-4053.	2.2	21
46	Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer. Cancer Management and Research, 2021, Volume 13, 7833-7839.	1.9	4
47	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 927-942.	5.4	40
48	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials, 2021, 22, 768.	1.6	13
49	Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Frontiers in Surgery, 2021, 8, 775527.	1.4	14
50	Quality Indicators for Bladder Cancer Services: A Collaborative Review. European Urology, 2020, 78, 43-59.	1.9	34
51	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. European Urology Oncology, 2020, 3, 131-144.	5.4	61
52	Platinum exposure and cause-specific mortality among patients with testicular cancer. Cancer, 2020, 126, 628-639.	4.1	28
53	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. European Urology, 2020, 77, 223-250.	1.9	132
54	Clinical Validation of a Urine Test (Uromonitor-V2®) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. Diagnostics, 2020, 10, 745.	2.6	25

#	ARTICLE	IF	CITATIONS
55	Reply to Francesco Montorsi, Marco Bandini, Alberto Briganti, et al. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. <i>Eur Urol</i> 2020;78:489-491. <i>European Urology</i> , 2020, 78, 492-493.	1.9	2
56	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	2.8	4
57	Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 935.e9-935.e16.	1.6	2
58	Lutetium-177-PSMA- α T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 884.	2.6	32
59	Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery?. <i>European Urology Oncology</i> , 2020, 3, 316-317.	5.4	6
60	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020, 78, 21-28.	1.9	239
61	Developments in the follow-up of nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 387-391.	1.8	3
62	Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future. <i>European Urology Oncology</i> , 2020, 3, 789-801.	5.4	3
63	Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020, 3, 318-340.	5.4	26
64	Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG). <i>BJU International</i> , 2020, 125, 497-505.	2.5	31
65	Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. <i>Journal of Urology</i> , 2020, 204, 685-690.	0.4	28
66	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 908-909.	0.4	0
67	A cost-effectiveness modeling study of robot-assisted (RARC) versus open radical cystectomy (ORC) for bladder cancer to inform future research. <i>European Urology Focus</i> , 2019, 5, 1058-1065.	3.1	20
68	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 51-60.	2.2	31
69	Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients. <i>European Urology Oncology</i> , 2019, 2, 483-489.	5.4	7
70	What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 625-642.	5.4	88
71	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
72	Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RT0G 0712-A Randomized Phase II Trial. <i>European Urology</i> , 2019, 75, 1033-1034.	1.9	0

#	ARTICLE	IF	CITATIONS
73	The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. <i>BMJ Open</i> , 2019, 9, e030396.	1.9	13
74	Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. <i>European Urology</i> , 2019, 75, 853-860.	1.9	68
75	Thermo Reversible Hydrogel Based Delivery of Mitomycin C (UGN-101) for Treatment of Upper Tract Urothelial Carcinoma (UTUC). <i>Bladder Cancer</i> , 2019, 5, 21-29.	0.4	6
76	Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 959-967.	2.5	63
77	Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2016;69:1046â€“52. <i>European Urology</i> , 2019, 75, e26.	1.9	0
78	Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need?. <i>European Urology</i> , 2019, 75, 72-73.	1.9	3
79	Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial. <i>European Urology Focus</i> , 2019, 5, 849-852.	3.1	2
80	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019, 5, 407-415.	3.1	23
81	Translation and validation of two disease-specific patient-reported outcome measures (Bladder) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Outcomes, 2019, 3, 62.	1.9	9
82	Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. <i>Bladder Cancer</i> , 2018, 4, 91-112.	0.4	33
83	Predicting Response to Intravesical Bacillus Calmette-GuÃ©rin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018, 73, 738-748.	1.9	112
84	Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. <i>International Journal of Hyperthermia</i> , 2018, 34, 988-993.	2.5	14
85	The conundrum of recurrent low-grade tumours. <i>Current Opinion in Urology</i> , 2018, 28, 557-562.	1.8	3
86	Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study. <i>Bladder Cancer</i> , 2018, 4, 365-376.	0.4	22
87	Performance of the Bladder EpiCheck, a Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. <i>European Urology Oncology</i> , 2018, 1, 307-313.	5.4	92
88	Risk of diabetes after para-aortic radiation for testicular cancer. <i>British Journal of Cancer</i> , 2018, 119, 901-907.	6.4	14
89	LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer. <i>Cancer Medicine</i> , 2018, 7, 3342-3350.	2.8	31
90	Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients. <i>European Urology Oncology</i> , 2018, 1, 231-237.	5.4	11

#	ARTICLE	IF	CITATIONS
91	A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model. <i>World Journal of Urology</i> , 2018, 36, 1719-1725.	2.2	7
92	Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model. <i>Therapeutic Advances in Urology</i> , 2018, 10, 213-221.	2.0	14
93	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq1 1 0.784314 rgBT / Over	1.9	372
94	Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzolaâ„¢) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 293-301.	0.4	10
95	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017, 71, 462-475.	1.9	1,241
96	BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. <i>Nature Reviews Urology</i> , 2017, 14, 244-255.	3.8	108
97	MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging. <i>World Journal of Urology</i> , 2017, 35, 703-711.	2.2	42
98	Reply to SÅawomir Poletajew, Piotr Radziszewski, Juan Palouâ€™s Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-GuÃ©rin for Adjuvant Treatment of Patients with Intermediate- and High-risk Nonâ€™Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2016;69:1046â€“52. <i>European Urology</i> , 2017, 71, e31-e32.	1.9	0
99	A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. <i>Oncotarget</i> , 2017, 8, 10565-10579.	1.8	26
100	Identification of long non-coding RNAs that stimulate cell survival in bladder cancer. <i>Oncotarget</i> , 2017, 8, 34442-34452.	1.8	12
101	The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer â€™ A New Analysis. <i>Bladder Cancer</i> , 2016, 2, 273-278.	0.4	46
102	Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. <i>Bladder Cancer</i> , 2016, 2, 77-89.	0.4	24
103	Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial nonâ€™muscleâ€™invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmetteâ€™GuÃ©rin: results from European Organisation for Research and Treatment of Cancer Genitoâ€™Urinary Group study 30911. <i>BJU International</i> . 2016. 118, 423-428.	2.5	28
104	Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides. <i>European Urology</i> , 2016, 69, 963.	1.9	0
105	Economic Burden of Bladder Cancer Across the European Union. <i>European Urology</i> , 2016, 69, 438-447.	1.9	223
106	Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial. <i>Health Expectations</i> , 2016, 19, 459-470.	2.6	39
107	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 nonâ€™muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e19-484.e25.	1.6	53
108	A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016, 64, 127-136.	2.8	67

#	ARTICLE	IF	CITATIONS
109	Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2016, 69, 1046-1052.	1.9	176
110	Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. <i>World Journal of Urology</i> , 2016, 34, 173-180.	2.2	37
111	Improving indication, technique and outcome of radical cystectomy. <i>Nature Reviews Urology</i> , 2016, 13, 74-76.	3.8	12
112	The Final Answer to the Question of Whether We Should Use a Single Postoperative Instillation of Chemotherapy After Resection of pTa and pT1 Bladder Tumors. <i>European Urology</i> , 2016, 69, 245-246.	1.9	1
113	Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. <i>European Urology</i> , 2016, 70, 233-245.	1.9	466
114	Fluorescence cystoscopy: the end of biopsies for carcinoma <i>in situ</i> detection?. <i>BJU International</i> , 2015, 116, 2-3.	2.5	2
115	Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue?. <i>Bladder Cancer</i> , 2015, 1, 97-103.	0.4	4
116	Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 204-209.e2.	1.9	17
117	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ MO urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 76-86.	10.7	323
118	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. <i>World Journal of Urology</i> , 2015, 33, 1411-1417.	2.2	10
119	Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasound-Guided Biopsy. <i>American Journal of Roentgenology</i> , 2015, 205, 57-63.	2.2	26
120	Management of Low-risk and Intermediate-risk Non-muscle-invasive Bladder Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 219-225.	2.2	9
121	The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 65.e9-65.e17.	1.6	35
122	Therapeutic Options in High-risk Non-muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Guérin. <i>European Urology</i> , 2015, 67, 359-360.	1.9	62
123	Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. <i>European Urology</i> , 2015, 67, 1112-1121.	1.9	270
124	Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 69.e19-69.e28.	1.6	58
125	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. <i>Nature Reviews Urology</i> , 2014, 11, 589-596.	3.8	69
126	Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2014, 6, 25-33.	2.0	31

#	ARTICLE	IF	CITATIONS
127	Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasoundâ€“Guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective. <i>European Urology</i> , 2014, 66, 430-436.	1.9	171
128	Safety of Hexaminolevulinate for Blue Light Cystoscopy in Bladder Cancer. A Combined Analysis of the Trials Used for Registration and Postmarketing Data. <i>Urology</i> , 2014, 84, 122-126.	1.0	18
129	Results of the European Basic Laparoscopic Urological Skills Examination. <i>European Urology</i> , 2014, 65, 490-496.	1.9	56
130	Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition. <i>Journal of Urology</i> , 2014, 191, 20-27.	0.4	98
131	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. <i>European Urology</i> , 2014, 65, 778-792.	1.9	868
132	The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 1065-1077.	1.9	164
133	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
134	The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-GuÃ©rin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911. <i>European Urology</i> , 2014, 66, 694-701.	1.9	68
135	Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations. <i>European Urology</i> , 2014, 66, 863-871.	1.9	72
136	Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 305-315.	0.4	82
137	<i>Reply to Sarah Willis, Alec Miners, and Jan van der Meulen's Letter to the Editor re: Maarten de Rooij, Simone Crienien, J. Alfred Witjes, Jelle O. Barentsz, Maroeska M. Rovers, Janneke P.C. Grutters. Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasoundâ€“guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.12.012. <i>European Urology</i>, 2014, 66, e30.</i>	1.9	2
138	Radical Cystectomy in a Dutch University Hospital: Long-Term Outcomes and Prognostic Factors in a Homogeneous Surgery-Only Series. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 190-195.	1.9	14
139	The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: An in vitro study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e1-49.e6.	1.6	9
140	Combined Chemohyperthermia: 10-Year Single Center Experience in 160 Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 708-713.	0.4	56
141	Interferon alfa in the treatment paradigm for nonâ€“muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 35.e21-35.e30.	1.6	40
142	Prognostic Relevance of Urinary Bladder Cancer Susceptibility Loci. <i>PLoS ONE</i> , 2014, 9, e89164.	2.5	20
143	Hexyl Aminolevulinateâ€“Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Nonâ€“Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. <i>European Urology</i> , 2013, 64, 624-638.	1.9	193
144	Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2013, 189, 2077-2082.	0.4	35

#	ARTICLE	IF	CITATIONS
145	Photodynamic Diagnosis of Non-muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data. <i>European Urology</i> , 2013, 64, 846-854.	1.9	372
146	Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (<scp>NMIBC</scp>) with emphasis on the use of bacillus <scp>C</scp>almette-<scp>G</scp>uÃ©rin (<scp>BCG</scp>): results of an international individual patient data survey (<scp>IPDS</scp>). <i>BJU International</i> , 2013, 112, 742-750.	2.5	87
147	Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1257-1268.	2.4	4
148	Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2273-2279.	1.6	41
149	Treatment Options Available for Bacillus Calmette-GuÃ©rin Failure in Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 1088-1096.	1.9	67
150	Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy. <i>Journal of Urology</i> , 2012, 188, 58-62.	0.4	158
151	Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 247-251.	1.6	39
152	Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 285-289.	1.6	60
153	Value of multimodality MRI and MR-guided biopsy at inclusion in an active surveillance protocol for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 105-105.	1.6	0
154	A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group. <i>Journal of Urology</i> , 2011, 186, 2158-2167.	0.4	247
155	Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. <i>BJU International</i> , 2011, 108, 1210-1214.	2.5	7
156	The Role of a Combined Regimen With Intravesical Chemotherapy and Hyperthermia in the Management of Non-muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2011, 60, 81-93.	1.9	166
157	Long-term Cancer-specific Survival in Patients with High-risk, Non-muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review. <i>European Urology</i> , 2011, 60, 493-500.	1.9	274
158	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. <i>Human Molecular Genetics</i> , 2011, 20, 4268-4281.	2.9	134
159	Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. <i>Current Opinion in Urology</i> , 2010, 20, 437-442.	1.8	28
160	Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations. <i>European Urology</i> , 2010, 57, 607-614.	1.9	117
161	An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-GuÃ©rin for Non-muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2009, 56, 247-256.	1.9	527
162	Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2009, 27, 337-342.	2.2	35

#	ARTICLE	IF	CITATIONS
163	Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party. <i>World Journal of Urology</i> , 2009, 27, 319-324.	2.2	98
164	Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 322-324.	1.6	6
165	Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin. <i>Journal of Urology</i> , 2009, 182, 1313-1317.	0.4	109
166	Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. <i>BJU International</i> , 2008, 101, 889-893.	2.5	21
167	Intravesical Pharmacotherapy for Non-Muscle-Invasive Bladder Cancer: A Critical Analysis of Currently Available Drugs, Treatment Schedules, and Long-Term Results. <i>European Urology</i> , 2008, 53, 45-52.	1.9	127
168	Comparison of Three Schedules of Intravesical Epirubicin in Patients with Non-Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2008, 53, 984-991.	1.9	67
169	The Schedule and Duration of Intravesical Chemotherapy in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials. <i>European Urology</i> , 2008, 53, 709-719.	1.9	162
170	Apaziquone for non-muscle invasive bladder cancer: a critical review. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1085-1096.	4.1	15
171	The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. <i>Nature Reviews Urology</i> , 2007, 4, 542-549.	1.4	103
172	Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response. <i>Journal of Urology</i> , 2006, 176, 1349-1353.	0.4	67
173	Hexyl Aminolevulinate in the Detection of Bladder Cancer. <i>Drugs</i> , 2006, 66, 579-580.	10.9	1
174	Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. <i>European Urology</i> , 2006, 49, 466-477.	1.9	2,360
175	Comparison of Hexaminolevulinate Based Flexible and Rigid Fluorescence Cystoscopy with Rigid White Light Cystoscopy in Bladder Cancer: Results of a Prospective Phase II Study. <i>European Urology</i> , 2005, 47, 319-322.	1.9	75
176	Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and Progressive Tumours and Implications for Therapy. <i>European Urology</i> , 2004, 45, 292-296.	1.9	235
177	Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 1999, 10, 295-304.	3.4	133
178	MULTIFOCAL TRANSITIONAL CELL CANCER AND p53 MUTATION ANALYSIS. <i>Journal of Urology</i> , 1998, 160, 124-125.	0.4	8
179	Current Recommendations for the Management of Bladder Cancer. <i>Drugs</i> , 1997, 53, 404-414.	10.9	21
180	Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the Bladder. <i>Journal of Urology</i> , 1995, 153, 929-933.	0.4	123